Crossmark

Tackling sepsis-associated AKI: are there any chances of REVIVAL with new approaches?

Published Online: 2024-01-10

Published Print: 2024-01

Authors

Prowle, John R. https://orcid.org/0000-0002-5002-2721
Bagshaw, Sean M.

Forni, Lui G.
License Information

Text and Data Mining valid from 2024-01-01

Version of Record valid from 2024-01-01
More Information

Article History

Received: 24 November 2023

Accepted: 25 November 2023

First Online: 10 January 2024

Declarations

:

: No external support was provided for the preparation of this manuscript. Dr Prowle reports consultancy or speakers fees from Baxter, bioMerieux, Paion UK, Mission Therapeutics Nikkiso, and Jafron Biomedical He serves as a paid Data Monitoring and Safety Board member for Novartis. Prof Bagshaw reports consultancy or speakers fees from Baxter, Bioporto, Novartis, Sea Star Medical and ShingoTec. Prof Forni reports consultancy or speakers fees from Exthera Medical, Baxter, Jafron Biomedical and ShingoTec.

Free to read: This content has been made available to all.

Document is current